Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Average Rating of "Moderate Buy" from Brokerages

Key Points

• Vera Therapeutics has received an average analyst rating of "Moderate Buy", with 8 buy ratings, 2 hold ratings, and 1 sell rating among 11 analysts covering the stock.
• The company's current market capitalization is $1.91 billion, with a recent trading price around $29.94 and a 12-month high of $51.61.
• Vera Therapeutics reported a quarterly loss of ($1.20) EPS, missing the consensus estimate, and analysts expect a projected loss of (-2.89) EPS for the current year.

Vera Therapeutics, Inc. (NASDAQ:VERA - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the eleven analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $61.50.

VERA has been the subject of several research reports. Weiss Ratings reiterated a "sell (d-)" rating on shares of Vera Therapeutics in a research note on Wednesday, October 8th. Wolfe Research reaffirmed a "peer perform" rating on shares of Vera Therapeutics in a report on Monday, August 4th. JPMorgan Chase & Co. lowered their price objective on Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Bank of America started coverage on Vera Therapeutics in a research note on Thursday, October 16th. They issued a "buy" rating and a $48.00 price objective on the stock. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Vera Therapeutics in a research report on Thursday, September 18th.

Vera Therapeutics Price Performance

VERA stock opened at $29.94 on Thursday. The business's fifty day moving average price is $26.03 and its 200 day moving average price is $23.57. The company has a market capitalization of $1.91 billion, a PE ratio of -8.36 and a beta of 1.23. The company has a current ratio of 17.03, a quick ratio of 17.03 and a debt-to-equity ratio of 0.16. Vera Therapeutics has a 12-month low of $18.53 and a 12-month high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.38). During the same quarter in the previous year, the company earned ($0.62) earnings per share. On average, sell-side analysts anticipate that Vera Therapeutics will post -2.89 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new position in shares of Vera Therapeutics during the 2nd quarter worth approximately $51,000. Quarry LP boosted its stake in Vera Therapeutics by 25.0% in the 1st quarter. Quarry LP now owns 2,500 shares of the company's stock valued at $60,000 after buying an additional 500 shares in the last quarter. AlphaQuest LLC increased its holdings in Vera Therapeutics by 404.7% in the first quarter. AlphaQuest LLC now owns 4,007 shares of the company's stock valued at $96,000 after purchasing an additional 3,213 shares during the last quarter. Virtus Investment Advisers LLC boosted its position in shares of Vera Therapeutics by 14.8% during the second quarter. Virtus Investment Advisers LLC now owns 4,176 shares of the company's stock worth $98,000 after buying an additional 539 shares during the period. Finally, Tower Research Capital LLC TRC raised its stake in Vera Therapeutics by 192.9% in the second quarter. Tower Research Capital LLC TRC now owns 4,186 shares of the company's stock valued at $99,000 after buying an additional 2,757 shares during the period. 99.21% of the stock is currently owned by hedge funds and other institutional investors.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.